Acute kidney injury in patients with cancer receiving anti-PD-1/PD-L1 antibodies: incidence, risk factors, and prognosis

References

• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:1–12. doi: 10.1146/annurev-pathol-042020-042741.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–362. doi: 10.1038/s41571-021-00473-5.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi: 10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi: 10.1016/j.ejca.2015.11.016.
   PubMed Web of Science ®Google Scholar
• Quach HT, Johnson DB, LeBoeuf NR, et al. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2021;85(4):956–966. doi: 10.1016/j.jaad.2020.09.054.
   PubMed Web of Science ®Google Scholar
• Sprangers B, Leaf DE, Porta C, et al. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat Rev Nephrol. 2022;18(12):794–805. doi: 10.1038/s41581-022-00630-8.
   PubMed Web of Science ®Google Scholar
• Levey AS, James MT. Acute kidney injury. Ann Intern Med. 2017;167(9):ITC66–ITC80. doi: 10.7326/AITC201711070.
   PubMed Web of Science ®Google Scholar
• Mercado MG, Smith DK, Guard EL. Acute kidney injury: diagnosis and management. Am Fam Physician. 2019;100(11):687–694.
   PubMed Web of Science ®Google Scholar
• Manohar S, Kompotiatis P, Thongprayoon C, et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant. 2019;34(1):108–117. doi: 10.1093/ndt/gfy105.
   PubMed Web of Science ®Google Scholar
• Ji MS, Wu R, Feng Z, et al. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study. Sci Rep. 2022;12(1):18752. doi: 10.1038/s41598-022-21912-y.
   PubMed Web of Science ®Google Scholar
• Seethapathy H, Zhao S, Chute DF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–1700. doi: 10.2215/CJN.00990119.
   PubMed Web of Science ®Google Scholar
• Meraz-Muñoz A, Amir E, Ng P, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020;8(1) doi: 10.1136/jitc-2019-000467.
   PubMed Web of Science ®Google Scholar
• Koks MS, Ocak G, Suelmann B, et al. Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study. PLoS One. 2021;16(6):e0252978. doi: 10.1371/journal.pone.0252978.
   PubMed Web of Science ®Google Scholar
• García-Carro C, Bolufer M, Bury R, et al. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant. 2022;37(5):887–894.
   PubMed Web of Science ®Google Scholar
• Shimamura Y, Watanabe S, Maeda T, et al. Incidence and risk factors of acute kidney injury, and its effect on mortality among japanese patients receiving immune check point inhibitors: a single-center observational study. Clin Exp Nephrol. 2021;25(5):479–487. doi: 10.1007/s10157-020-02008-1.
   PubMed Web of Science ®Google Scholar
• Seethapathy H, Zhao S, Strohbehn IA, et al. Incidence and clinical features of Immune-Related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors. Kidney Int Rep. 2020;5(10):1700–1705. doi: 10.1016/j.ekir.2020.07.011.
   PubMed Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–3391. doi: 10.1172/JCI80011.
   PubMed Web of Science ®Google Scholar
• Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced Non-Small-Cell lung cancer: current status and future directions. Oncologist. 2019;24(Suppl. 1):S31–S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
   PubMed Web of Science ®Google Scholar
• Zhe Lu, Guojun Zhang, Qunfeng Yao. The progress in cancer immunotherapy targeting PD-1/PD-L1 immune checkpoint. Journal of Modern Oncology. 2022;30(5):926–930.
   Google Scholar
• Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care. 2013;17(1):204. doi: 10.1186/cc11454.
   PubMed Web of Science ®Google Scholar
• Ye Du, Luyu Fu, Yidan Guo, et al. Clinical characteristics of acute kidney injury in cancer patients receiving immune checkpoint inhibitors. Chin J Nephrol. 2022;38(9):802–810.
   Google Scholar
• Sorah JD, Rose TL, Radhakrishna R, et al. Incidence and prediction of immune checkpoint inhibitor-related nephrotoxicity. J Immunother. 2021;44(3):127–131. doi: 10.1097/CJI.0000000000000338.
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385. doi: 10.1093/annonc/mdx286.
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–486. doi: 10.1038/nrclinonc.2016.58.
   PubMed Web of Science ®Google Scholar
• Gérard AO, Barbosa S, Parassol N, et al. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study. Clin Kidney J. 2022;15(10):1881–1887. doi: 10.1093/ckj/sfac109.
   PubMed Web of Science ®Google Scholar
• Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956–961. doi: 10.1038/ki.2010.89.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461–470. doi: 10.1038/nrneph.2010.71.
   PubMed Web of Science ®Google Scholar
• Ding H, Wu X, Gao W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin Immunol. 2005;115(2):184–191. doi: 10.1016/j.clim.2005.01.005.
   PubMed Web of Science ®Google Scholar
• Zhou L, Li Y, Gao Q, et al. Loop diuretics are associated with increased risk of Hospital-Acquired acute kidney injury in adult patients: a retrospective study. J Clin Med. 2022;11(13):3665.
   Web of Science ®Google Scholar
• Scott J, Jones T, Redaniel MT, et al. Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: a population based cohort study using the clinical practice research datalink. BMC Nephrol. 2019;20(1):481. doi: 10.1186/s12882-019-1633-2.
   PubMed Web of Science ®Google Scholar
• Dumoulin DW, Visser S, Cornelissen R, et al. Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC. J Thorac Oncol. 2020;15(9):1472–1483. doi: 10.1016/j.jtho.2020.04.021.
   PubMed Web of Science ®Google Scholar
• Liang W, Yu CJ, Wang QY, et al. Anemia is associated with increased risk of contrast‑induced acute kidney injury: a systematic review and meta-analysis. Bioengineered. 2021;12(1):648–661. doi: 10.1080/21655979.2021.1883887.
   PubMed Web of Science ®Google Scholar
• Han SS, Baek SH, Ahn SY, et al. Anemia is a risk factor for acute kidney injury and Long-Term mortality in critically ill patients. Tohoku J Exp Med. 2015;237(4):287–295. doi: 10.1620/tjem.237.287.
   PubMed Web of Science ®Google Scholar
• Botticelli A, Cirillo A, Strigari L, et al. Anti-PD-1 and anti-PD-L1 in head and neck cancer: a network Meta-Analysis. Front Immunol. 2021;12:705096. doi: 10.3389/fimmu.2021.705096.
   PubMed Web of Science ®Google Scholar
• Rothschild U, Muller L, Lechner A, et al. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions. Swiss Med Wkly. 2018;148:w14625. doi: 10.4414/smw.2018.14625.
   PubMed Web of Science ®Google Scholar
• Sacco AG, Cohen EE. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3305–3313. doi: 10.1200/JCO.2015.62.0963.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint Inhibitor-Associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31(2):435–446. doi: 10.1681/ASN.2019070676.
   PubMed Web of Science ®Google Scholar
• Gupta S, Short S, Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9(10):e003467. doi: 10.1136/jitc-2021-003467.
   Web of Science ®Google Scholar
• Qin Z, Liu K, Xu X, et al. Incidence, predictors and 6-month overall outcome of acute kidney injury in chinese patients receiving PD-1 inhibitors. Future Oncol. 2022;18(16):1951–1962. doi: 10.2217/fon-2021-1004.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–647. doi: 10.1016/j.kint.2016.04.008.
   PubMed Web of Science ®Google Scholar
• Seethapathy H, Herrmann SM, Sise ME. Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management. Kidney Med. 2021;3(6):1074–1081. doi: 10.1016/j.xkme.2021.08.008.
   PubMedGoogle Scholar
• Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160–169. doi: 10.1159/000455014.
   PubMed Web of Science ®Google Scholar
• Oleas D, Bolufer M, Agraz I, et al. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-Centre experience. Clin Kidney J. 2021;14(5):1364–1370. doi: 10.1093/ckj/sfaa008.
   PubMed Web of Science ®Google Scholar